Aptevo Therapeutics Reports $20.2 Million Net Loss and Zero Revenue for Nine Months Ended September 30, 2025

Aptevo Therapeutics Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $20.2 million for the nine months ended September 30, 2025, compared to a net loss of $17.8 million for the same period in 2024. The company’s total revenue remained at zero, as it has not yet commercialized any products. Operating expenses increased to $11.0 million for the nine months ended September 30, 2025, up from $10.5 million in the prior year, primarily driven by higher research and development costs associated with its clinical candidate mipletamig and increased employee expenses.

The company’s cash and cash equivalents rose significantly to $21.1 million as of September 30, 2025, compared to $8.7 million at the end of 2024. This increase was largely attributed to successful financing activities, including approximately $32.7 million raised through various equity offerings during the nine months ended September 30, 2025. Notably, Aptevo raised $18.7 million in net proceeds during the third quarter alone, extending its cash runway into the fourth quarter of 2026. The company also reported an accumulated deficit of $269.2 million as of September 30, 2025.

In terms of operational developments, Aptevo is advancing its clinical pipeline, which includes two clinical candidates: mipletamig and ALG.APV-527. The mipletamig candidate is currently being evaluated in a Phase 1b/2 clinical trial for acute myelogenous leukemia (AML), with promising preliminary results indicating a high remission rate among patients. The company has also introduced two new trispecific T-cell engagers, APVO451 and APVO452, expanding its oncology portfolio to five CD3-targeting molecules. These developments reflect Aptevo's strategic focus on leveraging its ADAPTIR and ADAPTIR-FLEX platform technologies to create innovative immunotherapy candidates.

Looking ahead, Aptevo anticipates continued operating losses as it invests in the development of its product candidates. The company emphasized the need for additional funding to support its ongoing clinical trials and operational needs. It plans to explore various financing options, including potential collaborations and licensing agreements, to bolster its financial position. The management expressed confidence that its existing cash resources would be sufficient to meet projected operating requirements for at least the next twelve months, although it acknowledged the potential for increased capital needs depending on the progress of its clinical programs and market conditions.